

ANALYSIS OF STRUCTURED AND COMMENTED INDIVIDUALIZED DRUGS REVIEWS MADE BY HOSPITAL PHARMACY DEPARTMENT

MJ Gándara-LadronDeGuevara, S. Fénix-Caballero, E. Alegre-del Rey, M. Blanco-Castaño, C. Palomo-Palomo, J. GarciaDeParedes-Esteban, M. Camean-Castillo, E. Ríos-Sanchez, J. Díaz-Navarro, J. Borrero-Rubio.


HOSPITAL PHARMACY. HU PUERTO REAL. (CÁDIZ- SPAIN) **CP-134**

The structured and commented reviews (SCREV) are individual assessments for drugs not included in the Pharmacotherapeutic Guide (NIPG) and off-label drugs requested by prescribers, in order to approve their use

PURPOSE: The objectives were to describe SCREV performed and to estimate the economic impact derived from the recommendation of pharmacy.

MATERIAL AND METHODS:

- A three-year descriptive retrospective study was designed with SCREV performed in this period.
- SCREV contained information about indications (NIPG or off-label), efficacy, safety, convenience, costs, including alternatives and cost/utility analysis, with a limit of 40.000€/QALY.
- The final **recommendation of pharmacy** included :



In case C, the savings achieved using the average time of treatment were estimated.

In case D, the effectiveness and the economic impact associated to the use of drug were calculated.

RESULTS:

48 SCREV were analyzed , 17 off-label and 31 NIPG. The highest number of requests came from **Oncology (48%)**. The recommendations of pharmacy were: **16.6% A, 54.2% B, 18.75% C and 10.45% D**. The results are summarized in the table:

SCREV N=48	A Approval N=8 (16.6%)	B Conditional approval N=26 (54.2%)	C Refusal N=9 (18.75%)	D Negative opinion N=5 (10.45%)
cost 40.000€/ (QALY)	N=2 not calculated:N=6	N=8 not calculated:N=10 lower cost:N=8	N=8 lower cost:N=1	N=1 not calculated: N=4
No Alternatives treatments	N=3	N=13	N=0	N=2

Logo: Servicio Andaluz de Salud, CONSEJERÍA DE SALUD, Hospital Universitario de Puerto Real.

Logo: CIM 105-433

Consulta: _____ Fecha Solicitud: _____ Fecha Respuesta: _____

Informe realizado por: _____
Revisado por: _____

Paciente: _____ NHC / NUISA: _____
Médico: _____ Servicio: _____
Fármaco solicitado: _____
Indicación: _____ Pauta: _____
Otras características del paciente (comorbilidad, intolerancia previa, tto previo, etc.): _____
Coste del tratamiento: _____
¿Se considera que existen alternativas disponibles?: _____
¿Supera 40.000€/AVAC?: _____
Opinión o dictamen técnico del Servicio de Farmacia en relación a la solicitud: _____
Recomendación de Farmacia* _____
Decisión final de Dirección Médica (si procede)* _____

Farmaceutico responsable: _____ Jefe Servicio Farmacia: _____ V*EP Dirección Médica: _____

* A: aprobada. B: Aprobada con condiciones. C: No aprobada. D: No oportuna con sus características. La recomendación de Farmacia se traslada al prescriptor. Si muestra de acuerdo, podrá elevar el caso a Dir. Médica.

Ventajas e inconvenientes del uso, en estos pacientes, de:

	VENTAJAS	INCONVENIENTES
Criterios de selección primarios	EFICACIA	
	SEGURIDAD	
Criterios de selección secundarios	Conveniencia	
	Coste	

The savings achieved with **C recommendation** were **229.324€**. The economic impact of **D recommendation** (all of them offered to the patients before request) was **63.447€**. Their effectiveness measured by overall survival (OS), and progression-free survival (PFS) were **OS < 2months, PFS <5 months** in all cases.

CONCLUSIONS:

- Individual SCREV showed utility for taking complicated decisions about off-label and NIPG drugs use at hospital, with important savings achieved.
- More than a half of the drugs requests were approved with adjusted conditions of use.
- The cases with negative opinion of pharmacy showed low effectiveness.